Company Overview
Frencken Group Ltd is a Singapore-based precision engineering company that operates across multiple segments including semiconductors, medical devices, industrial automation, and analytical life sciences. The company serves as a key supplier to high-end equipment manufacturers, particularly in the semiconductor industry where it supports advanced lithography machine production.
Financial Performance and Outlook
Frencken’s 2H25 results came in largely within expectations, with revenue and profit after tax and minority interests (PATMI) reaching 103% and 99% of full-year forecasts respectively. The company reported stable 2H25 PATMI of S$19.2 million, representing a modest 1% year-on-year increase. This performance was driven by contrasting segment dynamics across the business portfolio.
The Positives
Industrial automation emerged as a standout performer, with revenue surging 76% year-on-year to S$26.3 million in 2H25. This impressive growth was primarily attributed to capacity ramp from the company’s data storage customer. However, following this order ramp in 2025, industrial automation revenue is expected to decline year-on-year in 1H26.
The medical segment also contributed positively, with 2H25 revenue increasing 7% year-on-year to S$65.4 million. This growth was driven by higher demand for X-ray and digital pathology equipment from China, demonstrating the company’s ability to capitalise on regional healthcare infrastructure investments.
Frencken’s financial position strengthened considerably, with net cash spiking 92% year-on-year to S$139.6 million. This improvement was driven by higher inventory sell-through, as inventory days decreased to 105 days in FY25 from 116 days in FY24. The company also increased debt repayment by 32% year-on-year to S$62.5 million in 2H25, reducing total debt to S$22.3 million in FY25 from S$86.6 million in FY24.
The Negative
The semiconductor segment experienced muted growth, with 4Q25 revenue declining 4% year-on-year to S$112 million. This decrease was attributed to an order recalibration from the company’s Netherlands customer. Additionally, the analytical life science segment faced headwinds with a 12% year-on-year decline in revenue due to sluggish demand amid lower research funding in the United States.
Investment Recommendation
Phillip Securities Research maintains a BUY recommendation with an upgraded target price of S$2.50, increased from the previous S$1.87. The research house believes the semiconductor segment will be Frencken’s main growth driver in FY26-27, expecting orders to pick up gradually and ramp in 2H26 when key customers ramp production of the most advanced lithography machines.
Frequently Asked Questions
Q: What is Phillip Securities Research’s recommendation and target price for Frencken Group?
A: Phillip Securities Research maintains a BUY recommendation with a target price of S$2.50, upgraded from the previous S$1.87.
Q: Which segment performed best in 2H25?
A: Industrial automation was the standout performer, with revenue surging 76% year-on-year to S$26.3 million, driven by capacity ramp from the company’s data storage customer.
Q: Why did the semiconductor segment underperform in 4Q25?
A: Semiconductor revenue declined 4% year-on-year to S$112 million due to an order recalibration from the company’s Netherlands customer, though this is believed to be transitory.
Q: How has Frencken’s financial position changed?
A: The company’s financial position strengthened significantly with net cash spiking 92% year-on-year to S$139.6 million, whilst total debt was reduced to S$22.3 million from S$86.6 million in FY24.
Q: What factors affected the analytical life science segment?
A: The analytical life science segment experienced a 12% year-on-year decline in revenue due to sluggish demand amid lower research funding in the United States.
Q: What is driving the medical segment’s growth?
A: Medical segment revenue increased 7% year-on-year to S$65.4 million, driven by higher demand for X-ray and digital pathology equipment from China.
Q: When does Phillip Securities Research expect the semiconductor recovery to begin?
A: The research house expects semiconductor orders to pick up gradually and ramp in 2H26, when key customers ramp production of the most advanced lithography machines.
Q: How does Frencken’s valuation compare to peers?
A: Frencken trades at 20x FY26 price-to-earnings ratio, representing an 18% discount to its peers’ average of 24x PE.
This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
This advertisement has not been reviewed by the Monetary Authority of Singapore.
